Since the start of the COVID-19 pandemic in Romania, MedLife has invested in research into the SARS-CoV-2 virus by conducting studies on the natural immunization of the population. One study was conducted, including the rate of vaccines in Suceava, which at one time became the epicenter of the Romanian epidemic.
MedLife invests in medical research. Scientific research on population immunization and differences between COVID-19 trials
Medlife sequenced the country’s stray viruses. During this period, specialists are working on a study that monitors the evolution of antibodies in people confirmed by the RT-PCR test, as well as the differences between the methods of serological tests.
Only scientifically validated information on the detection and development of antibodies to the SARS-CoV-2 virus can be used to limit the spread of the disease and specifically support health system agents.
Study on the natural immunization of the population for COVID-19
The first case COVID-19 was confirmed in Romania on 26 February. MedLife conducted its first study on the natural immunization of the Romanian population for COVID-19 in March 2020.
- The percentage of the population vaccinated for COVID-19 is very low at the level of the assessed sample in several regions of the country. % 2 sub. The results were confirmed by another study by the National Institute of Public Health in a larger sample, which showed that the population’s vaccine in August was less than 2%.
- (…) The serological analysis of antibodies is reliable, it can be considered as a complementary method for RT-PCR testing. Quick tests are not properly validated.
Study of the vaccine of the population of Suceava
It has become Suceava the epicenter of the epidemic Romania was the first country with the highest number of diseases at that time, in absolute value (3,438) and per thousand inhabitants (5.42).
Research shows that 20% of the population over the age of 25 in the municipality of Suceava was naturally immunized from COVID-19. At the same time, the immunity of the group will not be acquired too quickly, given the very large difference between the percentage obtained and the threshold of 60-70%, which should be achieved in order to achieve collective immunity.
In terms of the demographic profile of the people included, the most affected were those aged 45 to 54, among whom laboratory tests showed that there were antibodies for 29%. At the opposite pole are young people between the ages of 25 and 34, with a 3-fold lower level of natural immunization.
Study of genome sequencing of the SARS-CoV-2 virus
The genome sequence contributes to the development of future treatments and vaccines.
- The SARS-CoV-2 virus circulating in Romania certainly comes from Wuhan. In Romania, the virus has a sequence identity of 99.97%, the original virus identified in China, and an average of 9 mutations per genome have been identified, with a maximum number of 13.
- Most likely, the spread of the SARS-CoV-2 virus in Romania was local, through intra-community transmission in the regions of the country and less so through direct imports from abroad.
- It is very difficult for patients who have overcome the disease to be re-infected with SARS-CoV-2.
“We are very proud that a Romanian company has managed to conduct large-scale studies only with local specialists and resources, the entire research is carried out by the MedLife research division, respectively by Romanian specialists,” said Mihai Marcu, MedLife team president and CEO.
The content of the website www.mediafax.ro is for your personal information and use only. Yes prohibited republishing the content of this site in the absence of an agreement with MEDIAFAX. To obtain this agreement, please contact us at [email protected]